Analyst Price Targets — SOLV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 26, 2026 1:51 am | Brett Fishbin | KeyBanc | $97.00 | $78.91 | TheFly | Solventum upgraded to Overweight from Sector Weight at KeyBanc |
| January 20, 2026 10:11 am | — | Mizuho Securities | $100.00 | $79.48 | TheFly | Solventum upgraded to Outperform from Neutral at Mizuho |
| January 7, 2026 12:35 pm | — | Stifel Nicolaus | $105.00 | $83.16 | TheFly | Solventum price target raised to $105 from $88 at Stifel |
| December 2, 2025 10:42 am | Ryan Zimmerman | BTIG | $100.00 | $85.56 | TheFly | BTIG upgrades Solventum to Buy on better setup in 2026 |
| October 1, 2025 9:07 am | Kevin Caliendo | UBS | $77.00 | $73.00 | TheFly | Solventum initiated with a Neutral at UBS |
| July 15, 2025 10:10 am | Patrick Wood | Morgan Stanley | $103.00 | $73.68 | TheFly | Solventum upgraded to Overweight from Equal Weight at Morgan Stanley |
| March 3, 2025 1:37 pm | — | Mizuho Securities | $82.00 | $80.16 | TheFly | Solventum price target raised to $82 from $70 at Mizuho |
| February 28, 2025 12:23 pm | — | Wells Fargo | $75.00 | $79.75 | TheFly | Solventum price target raised to $75 from $73 at Wells Fargo |
| December 3, 2024 9:25 pm | Steven Valiquette | Mizuho Securities | $70.00 | $72.28 | TheFly | Solventum initiated with a Neutral at Mizuho |
| October 7, 2024 4:20 pm | Rick Wise | Stifel Nicolaus | $82.00 | $66.29 | TheFly | Solventum initiated with a Buy at Stifel |
Latest News for SOLV
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Solventum shares have traded sideways post-spin, as investors digest separation impacts, stranded costs, and recent capital allocation moves. Despite a $4.1B divestment and targeted $500M cost savings, 2025 results showed minimal free cash flow and only modest earnings growth. 2026 guidance calls for 2-3% organic sales growth and adjusted EPS of $6.50, but free cash flow remains weak at ~$200M.
Citigroup Inc. cut its stake in Solventum Corporation (NYSE: SOLV) by 37.1% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 169,090 shares of the company's stock after selling 99,558 shares during the quarter. Citigroup Inc. owned about 0.10% of
SOLV's Q4 earnings and revenues beat estimates, driven by organic growth across MedSurg, Dental and HIS, despite margins declined.
Solventum Corporation (SOLV) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.